
    
      Randomized double-blind controlled trial. Patients with unilateral Meniere's disease that
      suffer from recurring vertigo attacks are allocated to either a verum or a placebo device and
      are treated for 4 months. Before during and after the treatment period, subjective and
      objective audiovestibular function parameters are measured.
    
  